MARKET

CLDX

CLDX

Celldex
NASDAQ

Real-time Quotes | Nasdaq Last Sale

26.21
+1.01
+4.01%
After Hours: 28.20 +1.99 +7.59% 17:48 03/05 EST
OPEN
25.25
PREV CLOSE
25.20
HIGH
26.30
LOW
22.62
VOLUME
529.09K
TURNOVER
--
52 WEEK HIGH
30.17
52 WEEK LOW
1.500
MARKET CAP
1.04B
P/E (TTM)
-11.7983
1D
5D
1M
3M
1Y
5Y
Celldex Therapeutics Announces Fireside Chat Presentation at the H.C. Wainwright Global Life Sciences Conference
GlobeNewswire · 2d ago
Recurrent Glioblastoma Multiforme (GBM) Treatment Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027
Mar 05, 2021 (Market Insight Reports) -- The report for Recurrent Glioblastoma Multiforme (GBM) Treatment offers an assiduous analysis of contemporary market...
Market Insight Reports · 2d ago
Cancer Immunotherapies Market Analysis by Size, Status, Growth Rate and Forecast to 2026
Mar 04, 2021 (Market Insight Reports) -- The Latest Released Cancer Immunotherapies market study has evaluated the future growth potential of Global Cancer...
Market Insight Reports · 3d ago
The Daily Biotech Pulse: KemPharm ADHD Drug Gets The Nod, MediciNova Shelves Vaccine Study
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 2)
Benzinga · 4d ago
38.6% Return Seen to Date on SmarTrend Celldex Therapeu Call (CLDX)
SmarTrend identified an Uptrend for Celldex Therapeu (NASDAQ:CLDX) on January 28th, 2021 at $20.33. In approximately 1 month, Celldex Therapeu has returned 38.56% as of today's recent price of $28.17.
Comtex SmarTrend(R) · 6d ago
Hypopharyngeal Cancer Treatment Market 2021 Top Manufacturers Strategy, Industry Share, Growth Factors, Development Trends and 2027 Forecast| Industry Research Biz
Mar 02, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry.” The global “Hypopharyngeal Cancer...
The Express Wire · 6d ago
Global Anaplastic Astrocytoma Treatment Market 2020 Growth Analysis by Key Players, Globally Effective Factors, Trends, Business Plans and Forecast to 2025
Feb 24, 2021 (CDN Newswire via Comtex) -- Global Anaplastic Astrocytoma Treatment Market 2020 by Company, Type and Application, Forecast to 2025 delivers an...
CDN Newswire · 02/25 02:20
The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 22)
Benzinga · 02/23 12:25
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CLDX. Analyze the recent business situations of Celldex through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CLDX stock price target is 34.33 with a high estimate of 36.00 and a low estimate of 32.00.
EPS
Institutional Holdings
Institutions: 187
Institutional Holdings: 50.33M
% Owned: 127.20%
Shares Outstanding: 39.57M
TypeInstitutionsShares
Increased
33
8.69M
New
65
-418.04K
Decreased
24
1.94M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.94%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Chairman/Independent Director
Karen Shoos
Chief Executive Officer/President/Director
Anthony Marucci
Chief Financial Officer/Senior Vice President/Secretary
Sam Martin
Executive Vice President/Chief Scientific Officer
Tibor Keler
Senior Vice President/General Counsel
Freddy Jimenez
Senior Vice President/IR Contact Officer
Sarah Cavanaugh
Senior Vice President
Elizabeth Crowley
Senior Vice President
Margo Heath-Chiozzi
Senior Vice President
Ronald Pepin
Senior Vice President
Richard Wright
Senior Vice President
Diane Young
Independent Director
Keith Brownlie
Independent Director
Herbert Conrad
Independent Director
James Marino
Independent Director
Harry Penner
No Data
About CLDX
Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients. Its Glembatumumab vedotin (also referred to as CDX-011) is meant for the treatment of metastatic melanoma. Its Varlilumab (also referred to as CDX-1127) is an immune modulating antibody. Its earlier stage drug candidates in clinical development include CDX-1401, which is a targeted immunotherapeutic aimed at antigen presenting cells (APC) for cancer indications and CDX-301, which is an immune cell mobilizing agent and dendritic cell growth factor. It includes a multi-faceted tumor-associated macrophage (TAM) program. The Company's pipeline also includes CDX-0158 and CDX-3379, which are humanized monoclonal antibodies.

Webull offers kinds of Celldex Therapeutics, Inc. stock information, including NASDAQ:CLDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLDX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CLDX stock methods without spending real money on the virtual paper trading platform.